Metastatic Lung Adenocarcinoma Complicated by Severe Nivolumab Pneumonitis
This lung cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Subtype
- Adenocarcinoma
- Biomarkers
- Microsatellite stable; low tumor mutation burden; PD-L1 70%
- Sex
- Male
- Treatment
- chemotherapy, radiation, surgery and immunotherapy
Treatment course, step by step
- He received concurrent cisplatin and etoposide with 50.4 Gy radiation in 28 fractions, followed by right lobectomy.
- After metastatic progression, nivolumab 240 mg every 2 weeks was started.
- Severe steroid-refractory pneumonitis later improved with infliximab.
What happened, in summary
A 66-year-old man was diagnosed with Stage IIIA adenocarcinoma of the right upper lung, classified as T3N2M0. He received cisplatin and etoposide with 50.4 Gy of radiation in 28 fractions, followed by removal of the right upper lobe.
Several months later, the cancer progressed at multiple new sites and was classified as Stage IV. Testing showed a microsatellite-stable tumor with low tumor mutation burden and PD-L1 expression of 70%. Nivolumab 240 mg every 2 weeks was started.
On day 126 of nivolumab, he was admitted with worsening shortness of breath, severe fatigue, and nausea. Infection and cancer progression were not evident, and lung inflammation extended beyond the previous radiation field. The pneumonitis did not respond adequately to corticosteroids. Infliximab was then used and improved the severe treatment-related lung inflammation.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Lung Cancer 384 stories
- Chemotherapy for Stage 4 Lung Cancer 217 stories
- Chemotherapy for Lung Cancer 386 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer